Ideas

Clinuvel (CUV) is one of very few ASX-listed biopharma companies directly commercialising novel pharmaceuticals across the US and EU in a highly profitable manner. We initiate coverage with a Buy rating and a Price Target of PT $24.00.

Eagers announced it has entered into a non-binding agreement to acquire a portfolio of dealerships and key strategic properties located across Melbourne and the Mornington region of Victoria from a group of companies associated with Nick Politis.

AIS has reported preliminary September quarter 2023 production results from its four operations. Our target price lifts 4% to $0.30/sh and we retain our Buy recommendation.